AI Stock Analysis - Novo Nordisk (NVO)
Analysis generated January 21, 2026.
Novo Nordisk is a global healthcare company that engages in the research, development, manufacture, and marketing of pharmaceutical products. With a strong focus on diabetes care and hormone replacement therapy, Novo Nordisk is considered a significant player in the biopharmaceutical industry. The company operates in over 80 countries and delivers its products to more than 170 countries worldwide. Its key products include insulin, GLP-1 receptor agonists, and other diabetes-related medications, positioning it as a central entity in the global fight against diabetes.
Stock Alerts - Novo Nordisk (NVO)
 |
Novo Nordisk | January 24 News Alert: Novo Nordisk sued for allegedly monopolising diabetes drug Victoza |
|
Novo Nordisk | January 16 Price is up by 6.5% in the last 24h. |
|
Novo Nordisk | January 11 Job postings are down by 16% in the last couple of days. |
|
Novo Nordisk | January 7 Reddit mentions are up by 199% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Novo Nordisk
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 312 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 733,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 37 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 18,527 | Sign up | Sign up | Sign up |
| Facebook Followers | 767,119 | Sign up | Sign up | Sign up |
| Instagram Followers | 179,837 | Sign up | Sign up | Sign up |
| Reddit Mentions | 24 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,099 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 29,527 | Sign up | Sign up | Sign up |
| X Followers | 55,282 | Sign up | Sign up | Sign up |
| X Mentions | 197 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 43,900 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $647,000 | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 65,871 | Sign up | Sign up | Sign up |
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $62.89 |
| Target Price | Sign up |
| Volume | 13,340,000 |
| Market Cap | $277B |
| Year Range | $44.89 - $80.18 |
| Dividend Yield | 2.77% |
| PE Ratio | 16.96 |
| Analyst Rating | 57% buy |
| Earnings Date | February 4 '26 |
| Industry | Drug Manufacturers |
In the news
 |
Novo Nordisk: The Q4 Setup Favors Another Beat (Earnings Preview)January 25 - SeekingAlpha |
 |
Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The UnderdogJanuary 24 - SeekingAlpha |
 |
Novo Nordisk sued for allegedly monopolising diabetes drug VictozaJanuary 23 - BusinessLine |
 |
Novo Nordisk sued in US for allegedly monopolizing diabetes drug VictozaJanuary 23 - The Times of India |
 |
Novo Nordisk: This Run Is Just Getting StartedJanuary 22 - SeekingAlpha |
 |
Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk's patent expiryJanuary 22 - The Times of India |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 75B | 17.9B | 57.1B | 20B | 33.8B | 4.500 |
| Q2 '25 | 76.9B | 12.8B | 64B | 26.5B | 43.6B | 5.960 |
| Q1 '25 | 78.1B | 12.9B | 65.2B | 29B | 46B | 6.530 |
| Q4 '24 | 85.7B | 13B | 72.7B | 28.2B | 40.3B | 6.340 |
| Q3 '24 | 71.3B | 11.3B | 60B | 27.3B | 37.4B | 6.120 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$224.44 1.3% | 44 |
 |
Eli Lilly and CompanyLLY |
$1039.51 2.2% | 62 |
 |
PfizerPFE |
$26.5 2.4% | 51 |
 |
AstrazenecaAZN |
$95.6 1.5% | 49 |
 |
AbbVieABBV |
$223.93 1.4% | 53 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Lisa McClain |
Oct 22, 25 | Buy | $1K - $15K |
| Marjorie Taylor Greene |
Oct 21, 25 | Buy | $1K - $15K |
| Lisa McClain |
Sep 15, 25 | Sell | $1K - $15K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Novo Nordisk
The Market Cap of Novo Nordisk is $277B.
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 16.96.
Novo Nordisk will report its next earnings on February 4 '26.
Currently, the price of one share of Novo Nordisk stock is $62.89.
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 2.77%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
